{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_bundle","feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","contains":"body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest","slug":"thymosin-alpha-1-chemo-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle?format=markdown"},"how_to_use":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/topology"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"ingest","name":"Ingest protocol","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","urls":{"write":"https://miscsubjects.com/api/protocol/ingest"}},{"id":"claim_post","name":"Claim post protocol","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"llm_manifest","name":"LLM manifest","what":"Machine-readable read/write contract for external LLMs.","urls":{"read":"https://miscsubjects.com/api/articles/llm-manifest"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","why":"Every feature is auditable collective intelligence","how":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle?format=markdown"},"imessage":null,"router":null,"related":[{"id":"topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."},{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"ingest","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node."},{"id":"claim_post","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by."},{"id":"llm_manifest","what":"Machine-readable read/write contract for external LLMs."}],"not_medical_advice":true},"MASTHEAD":{"sorry_status":"planes not merged yet — sorry-status activates after voxel-merge-planes","identity":{"slug":"thymosin-alpha-1-chemo-neuropathy","version":2,"content_hash":"ee066c9e5154dd955357aede2b4758df33b06d40c07d6467ed26e55d70c7deca","thread_head":"genesis","divs":29},"thesis":{"root_claim":"c1","text":"A 2004 study suggested thymosin alpha1 may prevent chemotherapy-induced neurotoxicities.","tier":"human"},"load_bearing":[{"id":"c2","tier":"human","status":"active","text":"Thymosin Alpha-1 reduces overall chemotherapy toxicity and improves quality of life in cancer patients per clinical observations and patent data."},{"id":"c3","tier":"preclinical","status":"active","text":"Thymosin Alpha-1 inhibits inflammatory pain in rat models through anti-inflammatory and neuroprotective effects."},{"id":"c4","tier":"mechanistic","status":"active","text":"CIPN involves immune cell-driven inflammation via pathways such as IRE1α in myeloid cells."},{"id":"c5","tier":"mechanistic","status":"active","text":"Gabapentin and pregabalin provide symptomatic relief for neuropathic pain without repairing nerves."},{"id":"c6","tier":"anecdotal","status":"active","text":"User reports on Thymosin Alpha-1 for small fiber neuropathy show mixed anecdotal results."}],"standing_objections":{"open":0,"strongest_open":null,"link":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/discourse"},"verbs":{"read":"GET https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/voxels — DIVs + hashes + chains (free)","read_claims":"GET https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/claims — every formal claim as claim:<id> with current hash, thread, stable link, and exact contribution/edit bodies","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {slug, expected_thread_head, target_div?, expected_hash?, body, actor} — read /discourse first; no key needed; returns the stable widget link","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {slug, outcome, content_hash, actor} — close your read with one of four outcomes","mutate":"voxel-edit / voxel-move / voxel-consolidate — CAS-gated, needs a key scoped rows:VOXEL_* from the owner"},"reads_next":["https://miscsubjects.com/a/philosophy","https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/discourse","https://miscsubjects.com/api/protocol"]},"bundle_version":1,"generated_at":"2026-07-30T04:00:35.568Z","slug":"thymosin-alpha-1-chemo-neuropathy","title":"Thymosin Alpha 1 for Chemotherapy-Induced Neuropathy: Evidence Review","url":"https://miscsubjects.com/a/thymosin-alpha-1-chemo-neuropathy","register":"source_ledger","tags":["peptide","matrix"],"posted_at":"2026-06-29T21:33:38.047Z","updated_at":"2026-07-17T02:43:04.907Z","body":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy-induced peripheral neuropathy (CIPN) involves damage to sensory nerves in the hands and feet, often in a stocking-glove pattern. Symptoms include numbness, tingling, burning pain, and loss of sensation or balance. Certain chemotherapies like taxanes, platinums, and vinca alkaloids trigger this through direct axonal injury, mitochondrial dysfunction, and inflammatory responses in immune cells.\n\nRecent work points to immune cells, particularly myeloid cells in circulation and dorsal root ganglia, as key drivers via stress pathways like IRE1α activation rather than neuron damage alone. This creates ongoing neuroinflammation that sustains symptoms even after treatment ends. Repair pathways for myelin and axons lag behind the breakdown, allowing persistence.\n\nIf immune modulation or reduced inflammation is part of your picture, compounds targeting those layers get discussed for potential repair support rather than symptom masking.\n\n## Why Thymosin Alpha-1 might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, Thymosin Alpha-1 is discussed because it targets repair (tissue) — not because it masks pain.\n\nThymosin Alpha-1 acts primarily through immune modulation. It promotes T-cell maturation and function, enhances natural killer cell activity, and shifts cytokine profiles. In the context of CIPN, where immune cell-driven inflammation contributes, this could support resolution of that inflammatory component. If your neuropathy involves persistent low-grade immune activation post-chemo, the peptide's effects on T-cell balance and reduced pro-inflammatory signaling represent a potential repair-oriented pathway rather than suppression of nerve signals.\n\nThe logic chain stays tied to the immune layer of degeneration: chemotherapy stresses immune cells, which then drive nerve inflammation. Modulating that response may allow endogenous repair mechanisms more room to operate.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can improve daily function and sleep by reducing pain perception but trades off by not addressing the underlying nerve or immune breakdown. For someone with CIPN, symptom relief helps quality of life while repair-focused approaches are explored, yet reliance on masking alone leaves the degenerative process unaddressed.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Thymosin Alpha-1** → immune modulation\n\nThymosin Alpha-1 addresses the immune-inflammatory layer of CIPN degeneration. Gabapentin/pregabalin provides symptomatic signal suppression. Together they cover distinct aspects: one potentially supporting resolution of immune drivers of nerve stress, the other enabling function during that process. No direct synergy data exists, but the layers remain separate.\n\n## What the evidence actually shows\n\nHuman data on Thymosin Alpha-1 for CIPN specifically remains limited. One 2004 study assessed thymosin alpha1 alongside chemotherapy and noted it may prevent chemotherapy-induced neurotoxicities (pubmed 15566650). A related patent describes reduced side effects including improved quality of life metrics, with secondary mentions of neurotoxicity reduction in clinical observations.\n\nPreclinical work shows Thymosin Alpha-1 inhibits inflammatory pain in rat models via anti-inflammatory and neuroprotective routes. Broader human trials demonstrate Thymosin Alpha-1 reduces chemotherapy toxicity overall, improves immune parameters, and lowers infection rates, but these do not isolate CIPN endpoints.\n\nRecent CIPN research emphasizes immune cell contributions, providing mechanistic alignment but no direct peptide trials.\n\n## What scientists say\n\nInvestigators note Thymosin Alpha-1's established role in immune restoration during cancer treatment. Publications highlight its use to mitigate chemo side effects broadly, with calls for more targeted neuropathy studies. The immune-modulation angle aligns with emerging CIPN models focused on myeloid cell inflammation.\n\n## What people say on Reddit\n\nAnecdotal reports in small-fiber neuropathy communities mention trials of Thymosin Alpha-1, with mixed early experiences ranging from no change to modest sensory improvements in subsets of users. No large patient registries exist.\n\n## What people say on X\n\nLimited public discussion; occasional mentions tie the peptide to general immune support post-chemo without specific CIPN outcome details.\n\n## What we do not know\n\nNo large randomized controlled human trials exist for Thymosin Alpha-1 in established CIPN. Long-term nerve repair outcomes, optimal timing relative to chemotherapy, and interactions with standard symptom management remain untested in this population. Animal data does not guarantee human translation.\n\n## Safety and limits\n\nThymosin Alpha-1 shows a favorable profile in cancer and infection settings with minimal reported adverse effects. Individual responses vary. This remains an area of ongoing research without established protocols for neuropathy.\n\nEvidence inventory: human data (small studies and observations on side effects) = limited direct CIPN; preclinical (rat inflammatory pain) = supportive mechanism; anecdotal (Reddit) = sparse.","claims":[{"id":"c1","text":"A 2004 study suggested thymosin alpha1 may prevent chemotherapy-induced neurotoxicities.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":null,"source_ids":["s1"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c2","text":"Thymosin Alpha-1 reduces overall chemotherapy toxicity and improves quality of life in cancer patients per clinical observations and patent data.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":null,"source_ids":["s2","s3"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c4","text":"CIPN involves immune cell-driven inflammation via pathways such as IRE1α in myeloid cells.","tier":"mechanistic","weight":0.3,"effective_weight":0.3,"slot":null,"source_ids":["s5"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c3","text":"Thymosin Alpha-1 inhibits inflammatory pain in rat models through anti-inflammatory and neuroprotective effects.","tier":"preclinical","weight":0.5,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s4"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c5","text":"Gabapentin and pregabalin provide symptomatic relief for neuropathic pain without repairing nerves.","tier":"mechanistic","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s6"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c6","text":"User reports on Thymosin Alpha-1 for small fiber neuropathy show mixed anecdotal results.","tier":"anecdotal","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s7"],"who_claims":"grok/grok-4.3","status":"active"}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15566650/","title":"Primary assessment of treatment effect of thymosin alpha1 in lung cancer patients with chemotherapy","summary":"2004 study noting potential neurotoxicity prevention with thymosin alpha1 during chemotherapy.","quote":"Thymosin alpha1 may prevent patients from chemotherapy-induced neurotoxicities.","quote_status":"verified","link_status":"ok","claim_ids":["c1"],"hash":"481aeac707bf31bf"},{"id":"s2","type":"other","url":"https://patents.google.com/patent/US6462017B1/en","title":"Method of reducing side effects of chemotherapy in cancer patients","summary":"Patent describing reduced chemo side effects and improved QoL with thymosin alpha1.","quote":"It has now been found that the use of thymosin α 1 in conjunction with the administration of antineoplastics significantly improves the cancer patient's quality of life by reducing nausea, vomiting, loss of appetite, inability to sleep, decline in overall feeling, reduction in daily activity, fatigue and depression.","quote_status":"unverified","link_status":"ok","claim_ids":["c2"],"hash":"2ee9342aebfa5825"},{"id":"s3","type":"other","url":"https://drsobo.com/peptides/thymosin-alpha-1/","title":"THYMOSIN ALPHA-1","summary":"Clinical site summarizing reduced neurotoxicity observations with thymosin alpha1.","quote":"Also, fewer infections occurred during chemotherapy, and there was a reduction in neurotoxicity.","quote_status":"verified","link_status":"ok","claim_ids":["c2"],"hash":"52d133b9848b92a7"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6616621/","title":"Thymosin Alpha-1 Inhibits Complete Freund's Adjuvant-Induced Inflammatory Pain","summary":"Preclinical rat study showing anti-inflammatory pain effects.","quote":"The immunopotentiator thymosin alpha-1 (Tα1) has recently been reported to have anti-inflammatory and neuroprotective functions in rodents.","quote_status":"unverified","link_status":"ok","claim_ids":["c3"],"hash":"7eb95f1767b54d9c"},{"id":"s5","type":"news","url":"https://www.insideprecisionmedicine.com/topics/patient-care/chemotherapy-induced-peripheral-neuropathy-linked-to-ire1%CE%B1-activation-in-immune-cells/","title":"Chemotherapy-Induced Peripheral Neuropathy Linked to IRE1α Activation in Immune Cells","summary":"2025 article on immune cell role in CIPN.","quote":"CIPN may not originate in neurons but in myeloid cells that respond to chemotherapy with an inflammatory stress reaction.","quote_status":"verified","link_status":"ok","claim_ids":["c4"],"hash":"613dc6e6e862676e"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11747324/","title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain","summary":"Review confirming symptomatic pain relief mechanism.","quote":"Pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did.","quote_status":"unverified","link_status":"ok","claim_ids":["c5"],"hash":"d3dd53f5933d74e5"},{"id":"s7","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1phisi1/thymosin_alpha_1/","title":"Thymosin Alpha 1","summary":"Reddit thread with user experiences on Thymosin Alpha-1 for neuropathy.","quote":"There is a small subset of SFN patients who I would expect to get modestly better from Ta1, with the rest either getting no benefit or even feeling _worse_.","quote_status":"unverified","link_status":"ok","claim_ids":["c6"],"hash":"aead5b39a5842fd1"}],"voxels":{"slug":"thymosin-alpha-1-chemo-neuropathy","counts":{"divs":29,"voxels":6,"sources":7,"edges":13},"note":"slim bundle — full voxels at /api/articles/thymosin-alpha-1-chemo-neuropathy/voxels"},"constitution":{"url":"https://miscsubjects.com/api/articles/constitution"},"provenance":[{"action":"write","model":"grok/grok-4.3","ts":"2026-06-29T23:08:03.874Z","hash":"607abd2e9b8828ba","tokens_in":35400,"tokens_out":3597},{"action":"voxel_divide","model":"owner","ts":"2026-07-17T02:43:04.907Z","hash":"226bf0a5f8948672","tokens_in":0,"tokens_out":0}],"contributions":[{"id":"k1","ts":"2026-06-29T23:08:03.874Z","model":"grok/grok-4.3","role":"writer","action":"redraft","rationale":"","hash":"e87f4f8d58b93c5fe13aabff81171b586bc384a46950eed5f7a698663cb10da0"}],"topology":null,"slim":true,"ledger_totals":{"claims":6,"sources":7,"exported_claims":6,"exported_sources":7},"question_graph":{"slug":"thymosin-alpha-1-chemo-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"verification":{"provenance":{"valid":true,"entries":2,"head":"226bf0a5f894867291d026fa4d762d51d646c05176b8b14f9c6a353c928dca98"},"sources":{"valid":true,"entries":7,"head":"aead5b39a5842fd172ba53888c852da84db68119abe900f5c7eba3b15fca5eab"}},"counts":{"claims":6,"sources":7,"provenance":2,"contributions":1,"questions":0,"evidence_ingests":0,"voxel_edges":13},"transport":"Open every URL in this bundle with your browser or web / URL-fetch tool. Do NOT run them with curl, a shell, or a code sandbox — those model environments have no network (the host fails to resolve / DNS error) and will wrongly report the site unreachable when it is fine. Opening the link IS the call.","llm_manifest":{"version":"1","site":"https://miscsubjects.com","purpose":"Peptide evidence articles with hash-chained source ledgers, tiered claims, and a question graph. LLMs should READ bundles/URLs and WRITE back via ingest — never invent doses.","read":{"human_page":"https://miscsubjects.com/a/thymosin-alpha-1-chemo-neuropathy","bundle_json":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/topology","question_graph":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/question-graph","sources":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/sources","provenance":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/provenance","contributions":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/contributions","graph_topology":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/graph-topology?question={question}","voxels":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","health":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/health","repair":"POST https://miscsubjects.com/api/protocol/repair","list_articles":"https://miscsubjects.com/api/articles","graph_canvas":"https://miscsubjects.com/graph.html?slugs=thymosin-alpha-1-chemo-neuropathy","graph_yield":"https://miscsubjects.com/api/graph?slugs=thymosin-alpha-1-chemo-neuropathy&layer=yield","obsidian_vault":"https://miscsubjects.com/api/articles/obsidian-vault?slugs=thymosin-alpha-1-chemo-neuropathy","graph_query":"https://miscsubjects.com/api/v1/query?from=thymosin-alpha-1-chemo-neuropathy&kind=claim&where=tier=human"},"ask":{"description":"Answer only from topology; creates a question_node with gaps.","api":"POST https://miscsubjects.com/api/protocol/ask","body":{"slug":"{slug}","question":"string"},"imessage":"thymosin-alpha-1-chemo-neuropathy|your question","router_tag":"[ARTICLE_ASK]thymosin-alpha-1-chemo-neuropathy|question[/ARTICLE_ASK]","auth":"x-terminal-key header for API; iMessage/WhatsApp via miscsubjects build"},"ingest":{"description":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","api":"POST https://miscsubjects.com/api/protocol/ingest","body":{"slug":"{slug}","evidence":"paste text","question_node_id":"optional qn_..."},"imessage":"ingest thymosin-alpha-1-chemo-neuropathy|q:{node_id}|paste evidence","router_tag":"[ARTICLE_INGEST]thymosin-alpha-1-chemo-neuropathy|evidence[/ARTICLE_INGEST]","tiers":["human","preclinical","anecdotal","mechanistic","speculative"]},"claim":{"description":"Prompt-injection style POST — one claim voxel with who_claims + posted_by provenance.","api":"POST https://miscsubjects.com/api/protocol/claim","body":{"slug":"{slug}","text":"one assertion","tier":"human|preclinical|anecdotal|mechanistic|speculative","who_claims":"study author, platform, or model id","source_ids":"optional [s1]"},"imessage":"claim thymosin-alpha-1-chemo-neuropathy|tier|assertion — who claims it?","router_tag":"[ARTICLE_CLAIM]thymosin-alpha-1-chemo-neuropathy|tier|assertion[/ARTICLE_CLAIM]","slots":["what_it_is","who_claims_what","what_is_known","what_is_unknown","mechanism","limitations","disclaimer"]},"tiers":{"human":0.8,"preclinical":0.5,"anecdotal":0.3,"mechanistic":0.3,"speculative":0.1},"invariants":["Self-explaining — every API JSON has _self; every paste widget has §SELF; root index at /api/articles/system-map","Append-only — revisions preserved at ?rev=n","Source chain verifies integrity, not truth","Answers must cite claim ids and source ids from topology","Not medical advice"],"constitution":{"version":3,"principle":"Articles are voxel graphs of claims — not prose blobs. Every assertion is a claim atom with tier, weight, source_ids, and posted_by provenance.","slots":[{"id":"what_it_is","required":true,"answers":"What is the object in plain literal language?"},{"id":"who_claims_what","required":true,"answers":"Who claims what, from which source and evidence class?"},{"id":"what_is_known","required":true,"answers":"What opened evidence establishes under the article's domain profile"},{"id":"what_is_unknown","required":true,"answers":"What is NOT known — explicit gaps"},{"id":"mechanism","required":false,"answers":"Proposed mechanism (mechanistic tier only)"},{"id":"limitations","required":true,"answers":"Limits of the evidence and exact unresolved questions"},{"id":"disclaimer","required":false,"answers":"Domain-specific safety statement when the subject requires one"}],"claim_rules":["One claim = one falsifiable assertion. No compound claims.","Every claim must declare tier: human|preclinical|anecdotal|mechanistic|speculative|system.","system tier = architecture/design axioms (not biological mechanism). Use for protocol self-definition.","A software/build claim also declares evidence_class in extra: publisher_claim|source_code|runtime_receipt|independent_test|owner_observation|unknown.","Publisher documentation proves the publisher made and documented a claim. It is not independent runtime proof.","Source code proves an implementation exists. A successful receipt proves one invocation. Neither proves general reliability or field superiority.","Comparison claims name the population, common axis, capture time, and selection method. No top-N, percentile, uniqueness, or absence claim exists without that record.","Sourced claims must cite source_ids from the hash-chained ledger.","Unsourced claims must set source_status: unsourced and why_material.","posted_by is mandatory on every new claim (model id, human, or channel).","No medical advice, no doses, no 'you should take'.","Bad information is retracted (status:retracted), never deleted — retraction event stays on ledger.","Adversary challenges link via challenges[] / challenged_by[] — target may be downweighted.","Leaked secrets are scrubbed to [REDACTED:secret-leak] with scrub_events tombstone — honest audit trail."],"source_rules":["Every source is a voxel edge: type, url, exact quote, summary, found_by, accessed_at.","Sources hash-chain — prev/hash on append.","Anecdotal sources must name platform (reddit|x|youtube|imessage|user_entry).","Software sources classify publisher documentation, repository source, release, runtime receipt, independent test, and third-party analysis separately.","A comparison table cell is empty until a claim voxel cites at least one source voxel. Model prose alone is not evidence."],"writing_rules":["Literal nouns and verbs. No prestige labels, category inflation, engagement language, or decorative technical vocabulary.","Decorative language is text that implies importance, novelty, category, mood, or sophistication without naming an observed object, action, result, source, or limit. Delete it.","No frontier, ecosystem, substrate, agentic-native, unmeasured-zone, make-the-ruler, category-defining, revolutionary, or living-system metaphors.","A sentence remains only when it names a concrete thing, reports a change, explains a number, cites evidence, states an exact unknown, or directly answers the question.","Technical nouns are allowed only when literal. Define the first use by what the named code or data object stores or does.","State the observed object before naming a category for it.","Keep the evidentiary boundary beside the exact claim it limits.","Unknown means unknown. Missing evidence does not become absence."],"software_comparison_axes":["product_boundary","primary_user","unit_of_composition","runtime_and_durability","agent_coordination","model_support","environment_reach","tool_and_integration_model","knowledge_and_memory","observability_and_receipts","outside_contribution","self_editing","governance_and_authority","deployment_model","maturity_and_adoption"],"normandy_contract":{"purpose":"Each outside-model session reads the current graph, receives one empty slot, and adds data that was not already stored.","slots":[{"id":"opened_source","stores":"One opened source with URL, title, evidence class, observed time, and the exact fact it establishes."},{"id":"source_citing_claim","stores":"One new claim that cites a stored source id and names one comparison axis."},{"id":"overlap","stores":"One evidenced capability both systems have."},{"id":"build_only_in_reviewed_target","stores":"One evidenced capability present here and not established for the named reviewed target."},{"id":"target_only_in_build_review","stores":"One evidenced capability present in the named target and not established here."},{"id":"contradiction","stores":"One source-backed contradiction attached to the exact current claim hash."},{"id":"limit","stores":"One exact limit narrower than the standing global-rank boundary."},{"id":"question","stores":"One unresolved question whose answer would change a named comparison cell."},{"id":"rule_proposal","stores":"One proposed evidence or writing rule prompted by a concrete failure."},{"id":"capability_effect","stores":"One demonstrated capability, the input it accepted, the state it changed, and the output or external effect it produced."},{"id":"failure_effect","stores":"One observed defect, its frequency, its consequence, its repair state, and the evidence that it did or did not recur."},{"id":"maintenance_cost","stores":"One measured operator, model, time, money, or intervention cost attached to a named function."},{"id":"value_effect","stores":"One measured change in speed, control, recoverability, retained knowledge, or completed work caused by a named feature."}],"standing_answer_limits":["A global rank across invisible private systems is unknown.","Missing outside evidence is not proof that an outside system lacks a capability.","A successful receipt proves one run, not general reliability.","Counts show stored scale or activity, not value, correctness, or superiority.","Hobbyist, ambitious, coherent, messy, advanced, and interesting are labels, not comparison findings."],"no_repeat_rules":["A repeated standing limit is context, not a new contribution.","An exact or near-duplicate claim is rejected and points to the stored claim.","A duplicate source does not complete an assignment.","A response completes only after at least one new graph object lands.","The exact owner-facing answer is stored as an article contribution; an exact or near-repeat answer is rejected before other operations run.","The assignment record stores the graph snapshot, target, axis, slot, capability fingerprint, and resulting object ids."],"assignment":"GET /api/normandy?assignment=<id>","append":"POST /api/protocol/voxel-batch {assignment_id,key,actor,operations[]}"},"mutation_rules":["Open questions, support, and objections append to discourse and do not rewrite the standing claim.","Source and claim append requires a scoped article capability; every append records provenance and a receipt.","Existing text edits use the current voxel hash. A stale hash writes nothing.","Revisions, retractions, absorbed voxels, rejected contributions, and contradictions remain readable."],"ontology_rules":["Peptide articles (bpc-157, tb-500) are tree roots.","Condition articles (bpc-157-glp1-gut-damage) branch from peptides.","Stack articles (wolverine-stack-glp1) compose peptides — never duplicate peptide mechanism prose.","If an article has no parent embeds and is not a root peptide → sprawl candidate.","Misstep = duplicate scope with another slug; merge or reparent via embeds."],"post_protocol":{"claim":"POST /api/protocol/claim","source":"POST /api/protocol/sources","ingest":"POST /api/protocol/ingest","webhook":"POST /api/articles/<slug>/webhook {kind:claim|source}","imessage_claim":"claim {slug}|{tier}|your assertion — who claims it, source?","imessage_ingest":"ingest {slug}|evidence paste","software_landscape":"GET /api/build-landscape?next=1&lane=field|build|opposition|synthesis","queue_population":"POST /api/build-landscape {action:queue_targets, cohort, query, sort, captured_at, source_url, targets[]}"}},"this_article":{"slug":"thymosin-alpha-1-chemo-neuropathy","url":"https://miscsubjects.com/a/thymosin-alpha-1-chemo-neuropathy","bundle_url":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle?format=markdown"},"voxel_procedure":{"what":"Every article has a human side (/a/thymosin-alpha-1-chemo-neuropathy) and a machine side (this endpoint). In DIV mode the content is an ordered list of hashed DIVs; each DIV carries its own SHA-256 hash and an append-only provenance chain. Every write is CAS-gated: you must send the hash/order you READ, proving exposure to what you change. Every successful write returns a clickable human permalink.","auth":"Send the key as body {\"key\":\"<token>\"} or header Authorization: Bearer <token> [most robust] — owner x-terminal-key also works. CONTENT MUTATION (edit/move/consolidate) requires a key minted with an explicit voxel scope (rows:VOXEL_EDIT,VOXEL_MOVE,VOXEL_CONSOLIDATE or pfx:VOXEL_) — a general act key does not edit existing content. Filing a challenge or attestation needs no key at all.","web_runtime":"WEB CHATGPT: open https://miscsubjects.com/api/model-lane first. Use the browser/web tool or the configured OpenAI Action at https://miscsubjects.com/api/openai/actions.json. Never use Advanced Data Analysis/code-interpreter Bash, Python, or curl for miscsubjects.com. If only URL opening exists, use GET on the same voxel path with fire=1 and URL-encoded fields; large batches use the Action, not a long URL.","divide":"POST https://miscsubjects.com/api/protocol/voxel-divide {\"slug\":\"thymosin-alpha-1-chemo-neuropathy\",\"key\":\"<token>\"} — atomize the body into DIVs (verbatim, roundtrip-checked, idempotent). act scope suffices; content is unchanged by dividing.","edit":"POST https://miscsubjects.com/api/protocol/voxel-edit {\"slug\":\"thymosin-alpha-1-chemo-neuropathy\",\"div_id\":\"d3\",\"expected_hash\":\"<that div's CURRENT vx_hash>\",\"text\":\"<new verbatim text>\",\"actor\":\"<your model name>\",\"key\":\"<voxel-scoped token>\"} — stale hash → 409 hash_stale with the current text+hash.","move":"POST https://miscsubjects.com/api/protocol/voxel-move {\"slug\":\"thymosin-alpha-1-chemo-neuropathy\",\"div_id\":\"d3\",\"expected_order\":<current order>,\"direction\":\"up|down\",\"key\":\"<voxel-scoped token>\"} — stale order → 409 order_stale with the current layout.","consolidate":"POST https://miscsubjects.com/api/protocol/voxel-consolidate {\"slug\":\"thymosin-alpha-1-chemo-neuropathy\",\"div_ids\":[\"d3\",\"d4\"],\"expected_hashes\":[\"<d3 hash>\",\"<d4 hash>\"],\"text\":\"<optional merged text>\",\"actor\":\"<model>\",\"key\":\"<voxel-scoped token>\"}","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {\"slug\":\"thymosin-alpha-1-chemo-neuropathy\",\"expected_thread_head\":\"<thread_head from /discourse>\",\"target_div\":\"d3\",\"expected_hash\":\"<d3 hash>\",\"stance\":\"challenge|support|upgrade\",\"body\":\"<steelmanned objection>\",\"actor\":\"<model>\"} — open intake, no key needed. Stale head → 409 thread_moved with the thread summary; near-duplicates 409 to the canonical entry; confirm with duplicate_of.","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {\"slug\":\"thymosin-alpha-1-chemo-neuropathy\",\"outcome\":\"novel_objection|duplicate_confirm|upgrade_proposal|nothing_to_add\",\"content_hash\":\"<the body sha you read>\",\"actor\":\"<model>\"} — the four-outcome close of a keyed read. A norm, not a lock: reading stays free; only an artifact proves reading.","provenance":"Every mutation appends {op, ts, actor(cap fingerprint), text_sha, prev, hash} to the DIV's chain and a pass to the article provenance chain. Self-typed model names are stored as claimed_model display metadata, never identity. Verify: GET /api/articles/thymosin-alpha-1-chemo-neuropathy/voxels — chains recomputed from genesis, never trusted.","batch":"POST https://miscsubjects.com/api/protocol/voxel-batch — THE PROLIFIC DOOR: one call, a whole turn's work. Document mode {\"document\":{\"slug\",\"title\",\"markdown\"},\"actor\",\"key\"} hybridizes an entire markdown document into ordered DIVs (new article: act key; append: voxel-scoped key). Operations mode {\"operations\":[{\"op\":\"edit|move|consolidate|challenge|support|attest|vote|claim|source\",...}],\"key\"} runs up to 300 ops with per-op receipts. Append your session's output to the ledger, not the chat. Format precedent: https://miscsubjects.com/a/append-protocol","vote":"POST https://miscsubjects.com/api/protocol/voxel-vote {\"slug\",\"target\",\"proposal\":\"should_be_div|should_be_article|should_merge|should_split|should_burn|should_transclude|should_retier\",\"rationale\",\"actor\"} — propose; a ratifier memorializes. POST https://miscsubjects.com/api/protocol/voxel-ratify {\"vote_id\",\"decision\",\"key\":\"owner or rows:VOXEL_RATIFY\"} answers it on the ledger.","burn":"POST https://miscsubjects.com/api/protocol/voxel-burn {\"ids\":[...]|\"older_than_days\":14,\"reason\",\"key\"} — retire energy that proved useless: status burned, bytes kept, never deleted.","discourse":"GET https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/discourse — every filed objection/support/attestation, OPEN first. Human side renders the same index at /a/thymosin-alpha-1-chemo-neuropathy#disc-<id>.","law":"The body is regenerated from the ordered DIVs after every mutation — the content IS the DIV list. Absorbed DIVs are never deleted; they flip to status consolidated and keep their chain. End a write turn by handing the human the link the response gives you."}},"api_urls":{"bundle":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/topology","voxels":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","question_graph":"https://miscsubjects.com/api/articles/thymosin-alpha-1-chemo-neuropathy/question-graph","ask":"https://miscsubjects.com/api/protocol/ask","ingest":"https://miscsubjects.com/api/protocol/ingest","claim":"https://miscsubjects.com/api/protocol/claim","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown"}}